<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04083079</url>
  </required_header>
  <id_info>
    <org_study_id>PEG-rhG-CSF-01</org_study_id>
    <nct_id>NCT04083079</nct_id>
  </id_info>
  <brief_title>Cost-Effectiveness Study of PEG-rhG-CSF in Prophylactic Treatment of Neutropenia After Chemotherapy in Lymphoma</brief_title>
  <official_title>Cost-Effectiveness Study of Pegylated Recombinant Human Granulocyte Colony-stimulating Factor(PEG-rhG-CSF) in Prophylactic Treatment of Neutropenia After Chemotherapy in Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pharmacoeconomic research to explore the cost-effectiveness of PEG-rhG-CSF and
      rhG-CSF in prophylactic treatment of neutropenia in lymphoma patients. It should provide more
      scientific basis for clinical decision-making.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">April 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incremental Cost-Effectiveness ratio</measure>
    <time_frame>1 year</time_frame>
    <description>A comparison of the different strategies based on the incremental cost-effectiveness ratio (ICER), which is defined by the difference in costs between interventions, divided by the difference in their measured impact</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cost-Effectiveness ratio</measure>
    <time_frame>1 year</time_frame>
    <description>A comparison of the different strategies based on the cost-effectiveness ratio (ICER), which is defined by the difference in costs between interventions, divided by the difference in their measured impact</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity analysis</measure>
    <time_frame>1 year</time_frame>
    <description>A sensitivity analysis is a way of examining Sensitivity to Change in results due to changes in the parameter values applied within a certain scope.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of febrile neutropenia</measure>
    <time_frame>1 year</time_frame>
    <description>Incidence of febrile neutropenia （i.e. absolute neutrophil count＜0.5×10^9/L and temperature ≥38℃）in each cycle</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration time of febrile neutropenia</measure>
    <time_frame>1 year</time_frame>
    <description>Duration time of febrile neutropenia （i.e. absolute neutrophil count＜0.5×10^9/L and temperature ≥38℃）in each cycle</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of grade 3-4 neutropenia</measure>
    <time_frame>1 year</time_frame>
    <description>Incidence of grade 3-4 neutropenia（i.e. absolute neutrophil count＜1×10^9/L）in each cycle</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration time of grade 3-4 neutropenia</measure>
    <time_frame>1 year</time_frame>
    <description>Duration time of grade 3-4 neutropenia（i.e. absolute neutrophil count＜1×10^9/L）in each cycle</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative dosage intensity</measure>
    <time_frame>1 year</time_frame>
    <description>comparison between planned and actual chemotherapy dosage in each cycle</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Usage rate of antibiotics</measure>
    <time_frame>1 year</time_frame>
    <description>Usage rate of antibiotics during study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>1 year</time_frame>
    <description>incidence and severity of adverse events during study period</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <condition>Granulocyte Colony-Stimulating Factor</condition>
  <condition>Cost-Benefit Analysis</condition>
  <arm_group>
    <arm_group_label>PEG-rhG-CSF cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PEG-rhG-CSF primary/secondary prevention will be given 24-72 hours after each cycle for only once.
Dosage: 6mg for weight ≥45kg，3mg for weight ＜45kg, subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rhG-CSF cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rhG-CSF primary/secondary prevention will be given 24-72 hours after each cycle until absolute neutrophil count ≥2×10^9/L.
rhG-CSF treatment will be given when there is neutropenia until absolute neutrophil count ≥2×10^9/L.
Dosage: 5μg/kg/d, subcutaneous injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG-rhG-CSF</intervention_name>
    <description>Patients will be given PEG-rhG-CSF for primary/secondary prevention each cycle.</description>
    <arm_group_label>PEG-rhG-CSF cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhG-CSF</intervention_name>
    <description>Patients will be given rhG-CSF for either primary/secondary prevention or treatment once any neutropenia each cycle.</description>
    <arm_group_label>rhG-CSF cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-65 years

          -  histologically confirmed de novo Non Hodgkin's lymphoma (except highly aggressive
             lymphoma such as lymphoblastic lymphoma and Burkitt lymphoma)

          -  plan to be given 6-8 cycles of cyclophosphamide, doxorubicin, vincristine, and
             prednisone (CHOP) ± Rituximab (R)

          -  KPS ≥70

          -  plan continuous PEG-rhG-CSF or rhG-CSF adiministration after at least 3 cycles of
             treatment for neutropenia prophylactic treatment

          -  absolute neutrophil count≥1.5×109/L，platelet count ≥100× 109/L，hemoglobin≥90g/L，while
             blood cell count≥3.0×109/L，without bleeding signs

          -  adquate liver and renal function as protocol discribed

          -  no serious cardiovascular disease as protocol discribed

          -  under good mental conditions and informed consented

          -  potential benefit for subjects based on investigators' decision

        Exclusion Criteria:

          -  history of hematopoetic stem cell transplantationor organ transplantation

          -  uncontrollable infection

          -  allergic to study drugs or ingredients

          -  accepted any other investigational drug or participated another interventional study
             within 30 days during screening period

          -  other uncontrollable conditions judged by the investigator

          -  breast-feeding , pregnant or plan to be pregnant during study observation period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Weili Zhao, PhD</last_name>
    <phone>+86 021 6437045</phone>
    <phone_ext>610707</phone_ext>
    <email>zhao.weili@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ruijin hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pengpeng XU, MD, PhD</last_name>
      <phone>86-21-64370045</phone>
      <phone_ext>610707</phone_ext>
      <email>xpproc@msn.com</email>
    </contact>
    <investigator>
      <last_name>Weili ZHAO, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pengpeng XU, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 26, 2019</study_first_submitted>
  <study_first_submitted_qc>September 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2019</study_first_posted>
  <last_update_submitted>September 5, 2019</last_update_submitted>
  <last_update_submitted_qc>September 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Zhao Weili</investigator_full_name>
    <investigator_title>First Deputy Director，Hematology Department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

